FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912062181> ?p ?o ?g. }

• W2912062181 endingPage "3810" @default.
• W2912062181 startingPage "3802" @default.
• W2912062181 abstract "Abstract Purpose: The prognosis of metastatic osteosarcoma continues to be poor. We hypothesized that alpha-emitting, bone-targeting radium 223 dichloride (223RaCl2) can be safely administered to patients with osteosarcoma and that early signals of response or resistance can be assessed by quantitative and qualitative correlative imaging studies and biomarkers. Patients and Methods: A 3+3 phase I, dose-escalation trial of 223RaCl2 (50, 75, and 100 kBq/kg) was designed in patients with recurrent/metastatic osteosarcoma aged ≥15 years. Objective measurements included changes in standardized uptake values of positron emission tomography (PET; 18FDG and/or NaF-18) and single-photon emission CT/CT (99mTc-MDP) as well as alkaline phosphatase and bone turnover markers at baseline, midstudy, and the end of the study. Results: Among 18 patients enrolled (including 15 males) aged 15–71 years, tumor locations included spine (n = 12, 67%), pelvis (n = 10, 56%), ribs (n = 9, 50%), extremity (n = 7, 39%), and skull (n = 2, 11%). Patients received 1–6 cycles of 223RaCl2; cumulative doses were 6.84-57.81 MBq. NaF PET revealed more sites of metastases than did FDG PET. One patient showed a metabolic response on FDG PET and NaF PET. Four patients had mixed responses, and one patient had a response in a brain metastasis. Bronchopulmonary hemorrhage from Grade 3 thrombocytopenia (N = 1) was a DLT. The median overall survival time was 25 weeks. Conclusions: The first evaluation of the safety and efficacy of an alpha particle in high-risk osteosarcoma shows that the recommended phase II dose for 223RaCl2 in osteosarcoma is 100 kBq/kg monthly (twice the dose approved for prostate cancer), with minimal hematologic toxicity, setting the stage for combination therapies." @default.
• W2912062181 created "2019-02-21" @default.
• W2912062181 creator A5005194857 @default.
• W2912062181 creator A5012871384 @default.
• W2912062181 creator A5014394490 @default.
• W2912062181 creator A5026095888 @default.
• W2912062181 creator A5036049219 @default.
• W2912062181 creator A5043675371 @default.
• W2912062181 creator A5046099119 @default.
• W2912062181 creator A5054595254 @default.
• W2912062181 creator A5060957245 @default.
• W2912062181 creator A5065709859 @default.
• W2912062181 creator A5069036413 @default.
• W2912062181 creator A5071718357 @default.
• W2912062181 creator A5073301930 @default.
• W2912062181 creator A5073906112 @default.
• W2912062181 creator A5076426660 @default.
• W2912062181 creator A5087234749 @default.
• W2912062181 creator A5090167515 @default.
• W2912062181 date "2019-07-01" @default.
• W2912062181 modified "2023-10-11" @default.
• W2912062181 title "Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial" @default.
• W2912062181 cites W1193303306 @default.
• W2912062181 cites W1990046402 @default.
• W2912062181 cites W1995300172 @default.
• W2912062181 cites W1995835470 @default.
• W2912062181 cites W2017645361 @default.
• W2912062181 cites W2020979816 @default.
• W2912062181 cites W2027863358 @default.
• W2912062181 cites W2066418177 @default.
• W2912062181 cites W2116452300 @default.
• W2912062181 cites W2121651045 @default.
• W2912062181 cites W2123077801 @default.
• W2912062181 cites W2132022190 @default.
• W2912062181 cites W2136505615 @default.
• W2912062181 cites W2137998467 @default.
• W2912062181 cites W2141454098 @default.
• W2912062181 cites W2141788705 @default.
• W2912062181 cites W2147376175 @default.
• W2912062181 cites W2155903913 @default.
• W2912062181 cites W2158639339 @default.
• W2912062181 cites W2168801604 @default.
• W2912062181 cites W2169774426 @default.
• W2912062181 cites W2275327310 @default.
• W2912062181 cites W2340941770 @default.
• W2912062181 cites W23799480 @default.
• W2912062181 cites W2752867062 @default.
• W2912062181 cites W2773389902 @default.
• W2912062181 cites W2920212076 @default.
• W2912062181 cites W4256726715 @default.
• W2912062181 doi "https://doi.org/10.1158/1078-0432.ccr-18-3964" @default.
• W2912062181 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6606382" @default.
• W2912062181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30733229" @default.
• W2912062181 hasPublicationYear "2019" @default.
• W2912062181 type Work @default.
• W2912062181 sameAs 2912062181 @default.
• W2912062181 citedByCount "39" @default.
• W2912062181 countsByYear W29120621812019 @default.
• W2912062181 countsByYear W29120621812020 @default.
• W2912062181 countsByYear W29120621812021 @default.
• W2912062181 countsByYear W29120621812022 @default.
• W2912062181 countsByYear W29120621812023 @default.
• W2912062181 crossrefType "journal-article" @default.
• W2912062181 hasAuthorship W2912062181A5005194857 @default.
• W2912062181 hasAuthorship W2912062181A5012871384 @default.
• W2912062181 hasAuthorship W2912062181A5014394490 @default.
• W2912062181 hasAuthorship W2912062181A5026095888 @default.
• W2912062181 hasAuthorship W2912062181A5036049219 @default.
• W2912062181 hasAuthorship W2912062181A5043675371 @default.
• W2912062181 hasAuthorship W2912062181A5046099119 @default.
• W2912062181 hasAuthorship W2912062181A5054595254 @default.
• W2912062181 hasAuthorship W2912062181A5060957245 @default.
• W2912062181 hasAuthorship W2912062181A5065709859 @default.
• W2912062181 hasAuthorship W2912062181A5069036413 @default.
• W2912062181 hasAuthorship W2912062181A5071718357 @default.
• W2912062181 hasAuthorship W2912062181A5073301930 @default.
• W2912062181 hasAuthorship W2912062181A5073906112 @default.
• W2912062181 hasAuthorship W2912062181A5076426660 @default.
• W2912062181 hasAuthorship W2912062181A5087234749 @default.
• W2912062181 hasAuthorship W2912062181A5090167515 @default.
• W2912062181 hasBestOaLocation W29120621811 @default.
• W2912062181 hasConcept C126838900 @default.
• W2912062181 hasConcept C142724271 @default.
• W2912062181 hasConcept C2775842073 @default.
• W2912062181 hasConcept C2777760704 @default.
• W2912062181 hasConcept C2989005 @default.
• W2912062181 hasConcept C71924100 @default.
• W2912062181 hasConceptScore W2912062181C126838900 @default.
• W2912062181 hasConceptScore W2912062181C142724271 @default.
• W2912062181 hasConceptScore W2912062181C2775842073 @default.
• W2912062181 hasConceptScore W2912062181C2777760704 @default.
• W2912062181 hasConceptScore W2912062181C2989005 @default.
• W2912062181 hasConceptScore W2912062181C71924100 @default.
• W2912062181 hasFunder F4320332521 @default.
• W2912062181 hasIssue "13" @default.
• W2912062181 hasLocation W29120621811 @default.
• W2912062181 hasLocation W29120621812 @default.
• W2912062181 hasLocation W29120621813 @default.

• next